Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absorb, Acino, ACTEMRA, alemtuzumab, Argentina, ARZERRA, Asia, attached, auto, banc, bankruptcy, BART, BBB, benchmark, Biotech, bowel, Brian, Cal, catch, chart, Chugai, circumstance, cladribine, competitor, Consent, conservative, corroborated, CV, declaratory, Deutschland, dispersion, EC, efalizumab, emergence, en, exemplary, EXTAVIA, Facet, FDIC, fifteen, fingolimod, franchise, FSPNo, graph, herewith, hierarchy, highest, highlighted, Hoechst, Hungary, ICC, immaterial, immunotherapy, incidence, inquiry, instability, invalid, invalidation, kroner, lastly, Lehman, lifecycle, LINGO, MAb, mediation, mistakenly, mondoGen, mortgage, MSCRG, nonrecurring, occupancy, override, par, parcel, physical, pivotal, Posner, pre, Progenitor, publish, published, Qualitative, RAPTIVA, recurring, rehearing, reorganization, revocation, revoked, RIXUTAN, roll, Sanofi, sense, slated, speak, split, spot, spring, spun, survey, swap, Tex, tightening, TLGP, tocilizumab, TREANDA, UK, ulcerative, unadjusted, unchanged, unobservable, upgraded, vi, waged, Weston, white, wrote, Zimmer
Removed:
acceleration, accepting, activated, added, Adelman, adhesion, administering, advanced, affiliated, AFFIRM, aggressive, al, ANDA, andRule, animal, announcement, anti, appeal, applicant, applying, argument, arrange, artificially, Authorisation, avoiding, Berlex, bioavailability, bioequivalence, bloodstream, bone, Boston, Brown, Burt, campaign, captioned, cascade, CDAI, choose, close, closely, collection, comparative, comparing, comprise, confirming, conspired, constrain, convey, copy, coupon, Creation, CRIPTO, decedent, declared, deduction, demanded, died, dilution, Dr, Dunn, earning, ENCORE, enhancing, enlarging, entitle, entrepreneurial, essential, evaluated, exchanged, expressed, Faheem, forfeited, formation, formulation, fulfilled, fusion, GAAP, gadolinium, governing, Grill, guarantor, Hasnain, Hillerod, Hybridon, hyperintense, identity, idle, immunomodulatory, indenture, induction, inflating, inhibit, inhibiting, insulation, internet, intervene, intervention, John, Judge, judged, Keller, Kellogg, leader, length, lieu, Lobel, lymphoproliferative, lymphotoxin, Lynch, MAA, Maine, mantle, marrow, McDermott, MDS, Merrill, migrating, migration, misleading, Nassau, negligence, neublastin, neuropathic, NIMO, noncompliance, notifying, observation, observational, observed, opposed, organ, outplacement, page, patchwork, peripheral, personal, personally, phototherapy, physiology, Pillsbury, pioneer, plaque, play, pleaded, power, precursor, predominantly, prevented, priced, principle, proceed, prohibited, promote, promulgated, proper, prospective, purported, purportedly, radioimmunotherapy, randomized, Rastetter, recommend, reconsidered, redeem, redemption, referenced, regenerate, rejection, relied, repatriate, repatriation, representation, rescue, restarted, retreatment, retrospective, role, salary, scan, seal, sensory, SENTINEL, seq, shorten, signaling, solicited, solid, soluble, sought, spanning, specificity, stem, steroid, Street, subordinated, substitute, suffering, thereunder, tissue, TMC, today, tolerated, trained, transfer, transformed, transitional, unrepatriated, unsealed, unspecified, USP, Washington, Winthrop
Filing tables
Filing exhibits
- 10-K Annual report
- 4.4 EX-4.4 Amendment No. 2 to Amended and Restated Rights Agreement Between Biogen Idec and Mellon Investor Services LLC Dated As of January 22, 2009.
- 10.19 EX-10.19 Amendment to Biogen Idec Inc. 2008 Omnibus Equity Plan Dated October 13, 2008
- 10.25 EX-10.25 Amendment to Biogen Idec Inc. 2006 Non-employee Directors Equity Plan Dated October 13, 2008
- 10.30 EX-10.30 Amendment to Biogen Idec Inc. 2005 Omnibus Equity Plan Dated October 13, 2008
- 10.34 EX-10.34 Amendment to Biogen Idec Inc. 2003 Omnibus Equity Plan Dated October 13, 2008
- 10.45 EX-10.45 Amendment to Biogen, Inc. 1985 Non-qualified Stock Option Plan Dated October 13, 2008
- 10.51 EX-10.51 Biogen Idec Inc. Executive Severance Policy - U.S. Executive Vice President, As Amended Effective October 13, 2008.
- 10.52 EX-10.52 Biogen Idec Inc. Executive Severance Policy - International Executive Vice President, As Amended Effective October 13, 2008.
- 10.53 EX-10.53 Biogen Idec Inc. Executive Severance Policy - U.S. Senior Vice President, As Amended Effective October 13, 2008.
- 10.54 EX-10.54 Biogen Idec Inc. Executive Severance Policy - International Senior Vice President, As Amended Effective October 13, 2008.
- 10.59 EX-10.59 Second Amendment to Employment Agreement Between Biogen Idec and James C. Mullen Dated As of December 4, 2008
- 10.61 EX-10.61 Employment Agreement Between Biogen Idec Management Services GMBH and Hans Peter Hasler Dated October 15, 2008.
- 10.63 EX-10.63 First Amendment to Employment Agreement Between Biogen Idec and Cecil B. Pickett Dated As of October 28, 2008
- 10.66 EX-10.66 First Amendment to Employment Agreement Between Biogen Idec and Craig E. Schneier Dated October 8, 2008
- 21.1 EX-21.1 Subsidiaries
- 23.1 EX-23.1 Consent of Pricewaterhousecoopers LLP - an Independent Registered Public Accounting Firm
- 31.1 EX-31.1 Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 EX-31.2 Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 32.1 EX-32.1 Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
BIIB similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-4 (No. 333-107098) and Registration Statements on Form S-8 (Nos. 333-97211, 333-106794, 333-47904, 333-65494, 333-110432, 333-110433, 333-128339, 333-152456, 333-128339 and 333-140817) of Biogen Idec Inc. of our report dated February 6, 2009 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10 K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
Boston, Massachusetts
February 6, 2009